Tonix to discontinue development of TNX-102 SL for fibromyalgia
Tonix Pharmaceuticals said it will stop the development of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia following its failure in a phase 3 trial.
The company said it will continue developing the drug for posttraumatic stress disorder (PTSD).
Click on this link for more information.
